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ABSTRACT: Adults with b thalassemia major frequently have low BMD, fractures, and bone pain. The
purpose of this study was to determine the prevalence of low BMD, fractures, and bone pain in all thalassemia
syndromes in childhood, adolescence, and adulthood, associations of BMD with fractures and bone pain, and
etiology of bone disease in thalassemia. Patients of all thalassemia syndromes in the Thalassemia Clinical
Research Network, $6 yr of age, with no preexisting medical condition affecting bone mass or requiring
steroids, participated. We measured spine and femur BMD and whole body BMC by DXA and assessed
vertebral abnormalities by morphometric X-ray absorptiometry (MXA). Medical history by interview and
review of medical records, physical examinations, and blood and urine collections were performed. Three
hundred sixty-one subjects, 49% male, with a mean age of 23.2 yr (range, 6.1–75 yr), were studied. Spine and
femur BMD Z-scores < 22 occurred in 46% and 25% of participants, respectively. Greater age, lower weight,
hypogonadism, and increased bone turnover were strong independent predictors of low bone mass regardless
of thalassemia syndrome. Peak bone mass was suboptimal. Thirty-six percent of patients had a history of
fractures, and 34% reported bone pain. BMD was negativelyassociated with fractures but not with bone pain.
Nine percent of participants had uniformly decreased height of several vertebrae by MXA, which was asso-
ciated with the use of iron chelator deferoxamine before 6 yr of age. In patients with thalassemia, low
BMD and fractures occur frequently and independently of the particular syndrome. Peak bone mass is
suboptimal. Low BMD is associated with hypogonadism, increased bone turnover, and an increased risk for
fractures.
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INTRODUCTION
T
HE THALASSEMIA SYNDROMES are a group of congenital
hemolytic anemias characterized by the reduced or ab-
sent synthesis of one or more globin chains of hemoglo-
bin.
(1) The two most common forms are the a and b thal-
assemias. b Thalassemias include b thalassemia major (b
TM), b thalassemia intermedia (b TI), and E-b thalassemia
(E-b), and result from >200 mutations affecting the b glo-
bin gene cluster. The a thalassemia syndromes include he-
moglobin H disease (HbH, or three gene a thalassemia),
the co-inheritance of HbH disease with hemoglobin Con-
stant Spring (HbH/CS) or other nondeletional a-globin mu-
tations, and homozygous a thalassemia (Hz a).
The hallmark of thalassemia is an imbalance in a to b
globin production, with the severity of anemia related to
the degree of this imbalance. The variable phenotypic ex-
pression within and among the thalassemia syndromes re-
sults in a wide spectrum of anemia, which may require pe-
riodic or regular transfusions to sustain life.
(1) Typically,
patients with b TM, Hz a, and HbH/CS and some with E-b
require regular transfusions, whereas b TI and HbH are
transfused sporadically, if at all. Because there is no physi-
ologic means of excreting iron, transfusion therapy leads to
progressive iron overload and ultimately multiple endocri-
nopathies, and potentially, lethal hepatic and/or cardiac
complications. Iron chelation therapy with deferoxamine
(DFO), introduced in the mid-1960s, has changed the
course of transfusional iron overload, reducing iron excess
and dramatically prolonging survival.
(2,3)
Historically, b TM was associated with marked osseous
changes, and in particular, facial and limb deformities that
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543were attributed to bone marrow expansion and cortical
thinning caused by massive ineffective erythropoiesis.
(4,5)
The introduction of regular transfusion therapy in the mid-
1960s to maintain a near-normal hemoglobin level resulted
in diminution or prevention of bone deformities.
(6) There-
fore, the detection of low bone mass in many regularly
transfused and well-chelated b TM patients over the last
decade was quite unexpected.
(7,8) There is now a growing
awareness that many transfusion-dependent adult patients
with b TM and b TI suffer from long-standing bone pain
and low bone mass.
(9,10) The presence of low bone mass,
fractures, and bone pain (referred to collectively in this
paper as bone disease) in patients with other thalassemia
syndromes is unclear. Little is known about the prevalence
of low bone mass in children and adolescents with thalas-
semia or the current rate of fractures and associations with
bone mass and bone pain. Furthermore, the etiology of
bone disease in thalassemia is poorly understood. A num-
ber of studies have examined the effect of various condi-
tions on the pathogenesis of bone disease, including inef-
fective erythropoiesis, iron overload, treatment with DFO,
vitamin D concentrations, the inﬂuence of endocrinopa-
thies, such as hypogonadism and growth hormone deﬁ-
ciency, and the thalassemia genotype.
(11–17) The results
have frequently been contradictory, and the studies have
been hindered by small sample size and variable practice
regimens.
The Thalassemia Clinical Research Network (TCRN)
consists of ﬁve thalassemia centers in North America and
their associated satellite sites with access to patients having
both a and b thalassemia syndromes. The TCRN per-
formed a cross-sectional study of BMD, fracture, and bone
pain histories and vertebral morphology among its patients
to better understand the severity of bone disease in thalas-
semia and its etiology. The purpose of the study was to
determine the prevalence of low bone mass, fractures, and
bone pain across all ages and thalassemia syndromes and to
describe associations between bone mass and fractures. We
evaluated the associations of anemia, transfusion and che-
lation management, iron burden and related endocrinopa-
thies, and environmental and genetic factors with bone
mass, fractures, and pain. We also sought to identify
changes in bone turnover that are involved in the develop-
ment of bone disease in thalassemia. From these results, we
hope to develop future preventative strategies and more
effective treatment regimens.
MATERIALS AND METHODS
Study protocol
TCRN patients of all thalassemia genotypes, $6y ro f
age, were eligible for this study. Exclusion criteria included
pregnancy, any known preexisting medical condition
known to affect bone mass, and chronic systemic adminis-
tration of steroids. The protocol was approved by the
TCRN Data and Safety Monitoring Board and by the ethi-
cal review boards of all TCRN institutions. All participants
provided signed informed consent.
Study participants underwent a complete physical exami-
nation and measurement of BMD and vertebral morphom-
etry by DXA. A medical history was obtained by interview
and review of medical records. Dietary calcium intake was
estimated from a 46-item, self-completed food frequency
questionnaire. Physical activity was reported as very light,
light, moderate, active, or very active using a standard-
ized questionnaire. A fasting morning blood sample was
obtained for measurement of N-telopeptides (NTX),
C-telopeptides (CTX), bone-speciﬁc alkaline phosphatase
(BSALP), free thyroxine and thyroid-stimulating hormone
(TSH), IGF1, IGF binding protein 3 (IGFBP3), serum go-
nadotropins (luteinizing hormone [LH] and follicle-stimu-
lating hormone [FSH]), testosterone (males), 25-hydrox-
yvitamin D (25 vit D), 1,25-dihydroxyvitamin D (1,25 vit D),
intact PTH, serum calcium, phosphorus, ferritin, and trans-
ferrin receptor concentrations. A second morning void was
collected for measurement of urinary NTX and deoxypyr-
idinoline cross-links (D-Pyr). A 24-h urine collection was
performed for measurement of calcium excretion. Bone age
was determined from X-rays of the left hand and wrist of
participants <20 yr of age and read locally according to the
method of Greulich and Pyle.
(18)
Procedures
BMD and morphometry: BMD of the lumbar spine (L1–
L4; spine) and left proximal femur (femur), a lateral lumbar
scan (lat spine) for calculation of volumetric lumbar BMD,
and whole body BMC were measured by Hologic QDR
4500 scanners with Delphi software upgrades. The precision
of spine and femur BMD measurements was determined by
duplicate measurement of 140 and 138 subjects, respec-
tively. The root mean square errors (RMSEs) of spine
and femur BMD were 0.022 (CV = 4.6%) and 0.009 g/cm
2
(CV = 1.3%), respectively. Except for assessing precision,
only the ﬁrst of the two duplicate scans was used for statis-
tical analysis. The unanalyzed BMD images were processed
and analyzed by a single, blinded technologist and radiolo-
gist at a central processing center (Hospital for Special Sur-
gery, New York, NY, USA). BMD results were analyzed at
a distinct Data Coordinating Center (DCC).
The presence of vertebral fractures and deformities was
assessed by morphometric X-ray absorptiometry (MXA)
using Hologic Instant Vertebral Assessment (IVA). Find-
ings from T10 to L4 were analyzed by a single senior radi-
ologist (RS). The severity of deformities was graded using
the Genant method
(19): grade I, 20–25% reduction in ante-
rior, posterior, or midvertebral height; grade II, 25–40%
reduction; grade III, >40% reduction.
Laboratory assays: Urine and serum samples from each
participant were stored at –808C and analyzed as a batch at
a central facility. Serum NTX and CTX and urine NTX
were measured by a competitive inhibition, enzyme-linked
immunoabsorbent assay, D-Pyr by a solid-phase, enzyme-
labeled chemiluminescent immunometric assay, IGF1,
IGFBP3, and BSALP by a solid-phase, enzyme-linked
immunoassay (ELISA), 25 vit D by competitive radioim-
munoassay after extraction, 1,25 vit D by column chroma-
tography and radioimmunoassay, intact PTH by immu-
nochemiluminometric assay, and free T4, LH, FSH, and
TSH by high sensitivity heterogeneous sandwich separation
544 VOGIATZI ET AL.assay. Testosterone was measured by a solid-phase, com-
petitive radioimmunoassay. Serum ferritin levels were de-
termined by a radioimmunoassay (RIA, T-14; Ramco
Laboratories, Houston, TX, USA). Serum transferrin re-
ceptor concentrations were measured by an enzyme immu-
noassay (EIA; T-94; Ramco Laboratories).
Statistical analysis
Calculated variables: Patients with b thalassemia were
classiﬁed as having TM if they had received eight or more
transfusions during the 12 mo before entering the study or
as TI if less.
Body mass index (BMI) was calculated as kilograms per
meters squared. Anthropometric Z-scores were calculated
relative to age- and sex-speciﬁc norms for whites produced
by the CDC from NHANES III data. Midparental heights
were calculated as the average parental height ± 6.5 cm for
boys and girls, respectively. BMD Z-scores were calculated
relative to age-, sex-, and race-speciﬁc norms provided by
Hologic. Asian and Middle Eastern individuals were com-
pared with white norms. Bone age–adjusted BMD Z-scores
were calculated for participants <20 yr old using each par-
ticipant’s estimated bone age for selecting the appropriate
norm.
Right skewed blood and urine assay results were log-
transformed to reduce the inﬂuence of highly leveraged
points to better conform to the distributional assumptions
of the models applied. Vitamin D deﬁciency was deﬁned as
a 25 vit D concentration <11 ng/ml and insufﬁciency as a
concentration between 11 and 30 ng/ml. The presence of
hypogonadism, growth hormone deﬁciency, hypothyroid-
ism, hypoparathyroidism, or diabetes mellitus was deﬁned
as having an identiﬁed clinical history or prescribed treat-
ment. In addition, hypoparathyroidism was deﬁned as an
intact PTH level below normal range for our assay in the
presence of albumin-adjusted hypocalcemia (serum calcium
< 8.5 mg/dl). Among females, hypogonadism was deﬁned as
lack of spontaneous menses after the age of 16, having a
history of using hormone replacement therapy (HRT) for
failure to proceed through puberty or loss of menses before
age 40, or current use of HRT. Hypogonadism in males was
determined by the prescription of HRT (testosterone or
HCG) or by having a serum testosterone concentration
lower than established norms for age. Inadequate gonadal
steroid replacement in hypogonadal males was conﬁrmed
by having a serum testosterone concentration lower than
established norms for age despite prescribed HRT. Fasting
hyperglycemia (blood glucose > 126 mg/dl), having a history
of fasting hyperglycemia or of an abnormal glucose re-
sponse to oral glucose tolerance test (blood glucose > 126
mg/dl at 0 min or >200 mg/dl at 120 min), having a history
of prescribed therapy with oral hypoglycemics or insulin, or
current therapy with oral hypoglycemics or insulin was used
to determine the presence of diabetes. The diagnosis of
growth hormone deﬁciency in children with growth failure
was made after endocrine referral at each participating site
and appropriate testing.
Self-reported bone and joint pain during the 30 days be-
fore the study interview was classiﬁed as an ordinal pain
severity index according to the participant’s use of pain
medications as follows: no reported pain, reported pain not
requiring use of medications, pain treated with over-the-
counter medications, and pain treated with prescription
pain killers.
Analyses: Continuous variables were summarized as
means, SDs, and ranges. Categorical variables were sum-
marized as simple percentages. Analyses of DXA results
and bone turnover markers were analyzed in general linear
models controlling for age as a covariate using partial-linear
splines with either one node at age 20 yr for DXA results or
two nodes at ages 11 and 20 yr for bone turnover markers.
These intervals are the outer range of initiation and
completion of puberty across both sexes and matched
breakpoints in the distribution of the data. In addition to
age, analyses of whole body BMC included sex and race
(Asian, white, and other race) as covariates in all models.
Pairwise comparisons among least-square means of cat-
egorical predictors were adjusted for multiple comparisons
by the Tukey-Kramer method. Ages of peak bone mass
were estimated by locally linear generalized additive mod-
els,
(20) with bias-corrected and accelerated bootstrap
CIs.
(21) Age-dependent incidence of fractures was analyzed
in proportional means models,
(22) with age at study entry
included as a covariate in all models. Pain severity was
analyzed by ordinal logistic regression, with age and sex
included as covariates. Presence of vertebral fractures and
deformities identiﬁed by MXA were analyzed by binary
logistic regression with age as a covariate. Wald p values
and proﬁle likelihood CIs are reported from proportional
means and logistic regression models. Multiple regression
models were selected from all analysis variables by stepwise
regression with ﬁnal variable selection by the Bayesian in-
formation criterion.
Analyses were generally exploratory, with the aim of de-
scribing observed patterns in the data. Multiple comparison
corrections for the large number of models and outcome
measures analyzed were not made. All inferences were
based on two-tailed tests with a threshold of a =0 . 0 5f o r
declaring signiﬁcance. Analyses were conducted using SAS
(version 9.1.3; SAS Institute, Cary, NC, USA) and S-Plus
(version 7.0; Insightful, Seattle, WA, USA).
RESULTS
Participant characteristics
A total of 386 individuals consented to the study, and 372
completed the protocol, of whom 9 were excluded because
of prior stem cell transplantation, chronic use of systemic
steroids, or incomplete data. In addition, only two partici-
pants had Hz a and were not included in our analysis be-
cause their sample size precluded meaningful interpretation
of their data.
Characteristics of the 361 eligible participants who com-
pleted DXA scanning and had b,E - b, or common a thal-
assemias are presented in Table 1. Mean height and weight
were within 2 SDs of the general population mean for all
thalassemia syndromes. However, 95 participants (27% of
352 with height measurements) had signiﬁcant growth fail-
ure,with height Z-scores below22 SD.The meanbone age
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546 VOGIATZI ET AL.of children and adolescents was close to their chronological
age. Hypogonadism was the most frequent endocrinopathy,
affecting 34% of females and 38% of males. Vitamin D
deﬁciency (25 vit D < 11 ng/ml) and insufﬁciency (25 vit
D = 11–30 ng/ml) were found in 12% and 70% of partici-
pants, respectively. Growth hormone deﬁciency was pres-
ent in 9.6%, diabetes mellitus in 9.2%, hypothyroidism in
8.7%, and hypoparathyroidism in 1.4% of study partici-
pants. Twenty-nine adults were treated with a bisphospho-
nate.
Bone mass
Demographic proﬁle: Spine, femur, and whole body
BMD were close to age norms at age 6 yr. A strong negative
association between bone mass and age, which was more
marked in the age group 11–19 years of age was observed
(20.84 SD/5 yr; 95% CI, 21.10 to 20.59 SD; p < 0.001 for
whole body BMD among participants < 20 yr of age; Figs. 1
and 2). The rates of spine BMD Z-scores less than –2 in-
creased from 8.7% among participants 6–10 yr old to 44%
in those 11–19 yr old and 61% in patients >20 yr old. Above
age 20 yr, the association between spine BMD and age was
nearlyconstant relativeto age norms (20.008 SD/5 yr;95%
CI, 20.08–0.07 SD; p = 0.25; Figs. 1 and 2). Similar patterns
of BMD Z-scores versus age were observed for the femur.
Sex or race did not account for the differences in the spine
and femur BMD Z-scores. Norms for adult male whole
body BMD were not available, but among females, whole
body BMD Z-scores increased modestly but insigniﬁcantly
(p = 0.15) above age 20 yr, perhaps reﬂecting a survival
bias. Peak bone mass, estimated as the age with maximum
wholebody BMC,occurred at22.4 (95% CI,19.0–31.8) and
29.8 yr (95% CI, 23.5–34.0) among females and males, re-
spectively (Fig. 1C). Among participants 20–29 yr of age,
86% (75/87) had spine BMD Z-scores less than 21 SD,
indicating suboptimal peak bone mass.
Thalassemia syndromes: Low spine and femur BMD
(Table 2; Fig. 3) and whole body BMD were prevalent
among all thalassemia syndromes. Frequencies of BMD Z-
scores below 21 SD ranged from 58% to 80% for spine and
from 37% to 70% for femur. Whole body BMD normative
data were available only for children and adolescents and
adult females. Among children and adolescents, prevalence
of whole body BMD Z-scores below –1 SD was similarly
high across all thalassemia syndromes, ranging from 50% to
74%.
Estimated mean spine BMD Z-scores of a 20 yr old
ranged from 21.64 to 22.37 SD (mean [95% CI]: b TM,
22.37 [22.64,22.11]; b TI, 22.15 [22.56,21.75]; E-b, 22.34
[22.74,21.95];HbHDis,21.64 [22.16,21.11]; HbH/CS, 22.00
[22.52,21.49]), controlling for sex and race. Age-, sex-, and
race-adjusted BMD Z-scores and whole body BMC were
lower among b TM and E-b participants and higher among
b TI, HbH disease, and HbH/CS participants (spine, p =
0.062; femur, p = 0.028; whole body BMC, p = 0.025; Fig.
3), although individual pairwise comparisons were not sig-
niﬁcant after controlling for multiple comparisons. Spine
BMD Z-scores of b TM and TI participants did not differ
signiﬁcantly (p = 0.74).
Spine BMD was lower than femur BMD relative to their
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LOW BONE MASS AND FRACTURES IN THALASSEMIA 547norms (0.67 SD; 95% CI, 0.59–0.76 SD; p < 0.001). The
difference between spine and femur BMD Z-scores in-
creased signiﬁcantly across adolescence (p < 0.001) and was
greater among males than females (0.25 SD; 95% CI, 0.08–
0.42 SD; p = 0.004) but was not associated with race or
thalassemia syndrome.
Associations: Results of analyses of spine and femur
BMD Z-scores controlling for age, and whole body BMC
controlling for age, sex, and race are presented in Table 3.
These include associations with demographic, genetic, an-
thropometric, and environmental factors, transfusion and
chelation parameters, thalassemia-related endocrinopathies
and co-morbidities, markers of bone turnover, serum IGF1
and IGFBP3 concentrations, serum chemistry including Ca
and P, and 25 vit D concentrations. A number of positive
associations were observed (Table 3). Although hypogo-
nadism was negatively associated with BMD (Table 3), hy-
pogonadal participants who were on gonadal steroid re-
placement had the same BMD as untreated hypogondal
subjects. Participants with vitamin D deﬁciency had signiﬁ-
cantly lower BMD (Table 3). The relationship between 25
vit D and BMD Z-score (adjusted for age) was not linear,
reaching a plateau at 25 vit D concentrations >15 ng/ml.
Finally, no analysis identiﬁed any association between
treatment with bisphosphonates and bone mass.
Multiple regression analysis: Many of the important pre-
dictors of bone mass identiﬁed above covary. In multiple
regression models, age, weight Z-score, hypogonadism, and
markers of bone turnover were consistently strong and in-
dependent predictors of spine and femur BMD Z-scores
and whole body BMC (Table 4). Spine and femur Z-scores
had a strong negative association with age during adoles-
cence, were higher in heavier participants, and were lower
in hypogonadal participants and those with elevated uri-
nary D-Pyr (p < 0.001 for all). Whole body BMC results
were similar except that BSALP was a stronger indepen-
dent predictor than D-Pyr. In addition to these parameters,
25 vit D was an independent positive predictor of spine
BMD Z-scores; family history of osteoporosis was a nega-
tive predictor of femur BMD, whereas serum FSH concen-
trations were a positive predictor of both femur and whole
body BMC (Table 4).
Further analysis focused on participants <20 yr of age to
better understand the factors that may affect BMD during
adolescence. Among participants <20 yr old, age, weight
Z-score, and bone turnover rate continued to be strong,
independent predictors of bone mass, but hypogonadism,
family history of osteoporosis, and 25 vit D were no longer
signiﬁcant. Sex, race, BSALP, and FSH remained signiﬁ-
cant, independent predictors of whole body BMC.
Calendar age versus bone age: Spine BMD Z-scores in
children and adolescents were also analyzed after calculat-
ing a bone age-adjusted Z-score (BA Z-score) to control
for slow maturation of participants with growth-associated
endocrinopathies. This minimally reduced the percentage
of children and adolescents with spine and femur BMD
Z-scores below 21 SD from 65% to 59% and from 48% to
42%, respectively. Bone age–adjusted spine Z-scores con-
tinued to be strongly associated with anthropometric pa-
rameters, but signiﬁcant associations found in this age
group between hypogonadism, growth hormone deﬁciency,
IGF-1 levels, and bone turnover markers and calendar age
spine BMD Z-scores were not found with bone age–
adjusted spine BMD Z-scores.
Volumetric BMD: Areal spine BMD using an anterior-
posterior (AP) projection may underestimate true BMD in
small and growing individuals. Volumetric spine BMD, cal-
culated by combining AP and lateral lumbar projections,
may provide a more accurate assessment of BMD in such
individuals. Because norms for volumetric BMD were only
available for adult women, we studied possible bias in AP
estimates by testing for height dependence in the relationship
FIG. 1. Bone mass vs. age. (A and B) Spine BMD (g/cm
2) with
age-dependent reference norms for whites (solid line) and ±2 SD
(dashed lines) for males (A) and females (B). (C) Whole body
BMC (kg) with locally weighted regressions for males (solid line)
and females (dashed line). One individual age 75 yr is omitted
(symbols: male, u; female, s).
548 VOGIATZI ET AL.between AP and volumetric BMD. For a given AP BMD,
volumetric BMD is greater when height Z-scores are lower
(p = 0.001); however, the magnitude of difference is small
(0.005 g/cm
3/SD; 95% CI, 0.002–0.008 g/cm
3/SD) and does
not suggest an important effect of size on our ﬁndings.
Bone turnover markers
Serum and urinary concentrations of bone turnover
markers were plotted for all ages (Fig. 4), overlaying avail-
able normative data. Limited pediatric normative data are
available. Bone turnover is high during childhood and ado-
lescence compared with adults, reﬂecting rapid bone devel-
opment. Adults, regardless of the presence or absence of
hypogonadism, had substantially elevated levels of both
bone resorption and formation markers, indicating elevated
bone turnover.
Self-reported fractures
By participant self-reporting and review of medical rec-
ords, fractures occurred in 36% of participants, with 8.9%
reporting three or more lifetime fractures (Table 2). Ex-
tremity fractures were most common at 33%, followed by
back and hip fractures at 3.6%. The cumulative risk for
fractures increased almost linearly with age (p < 0.001).
Overall, no sex difference was seen; however, among par-
ticipants <20 yr of age, males were more likely to fracture
compared with females (mean ratio, 2.5; 95% CI, 1.1–5.6;
p = 0.026). Asian participants reported lower fracture rates
than whites (p = 0.025).
The fracture incidence rate varied signiﬁcantly among
the thalassemia syndromes (p = 0.014), with E-b and a
thalassemia participants having lower fractures rates com-
pared with b TM participants (mean ratio [95% C1]: E-b,
0.40 [0.20,0.81]; HbH/CS, 0.10 [0.01,0.70]). The prevalence
of a history of fractures among adults was 55% in TM and
71% in TI (Fig. 5); this difference was not signiﬁcant. The
effect of thalassemia syndrome was lost in multivariate
analysis.
Spine and femur BMD Z-score and total body BMC
were negatively associated with fracture rate. For a 1-SD
decrease in spine or femur BMD Z-score, the mean fracture
rate increased by 37% or 47%, respectively (p < 0.001 for
both). After controlling for age, higher D-Pyr concentra-
tions, hypogonadism, histories of medicated heart disease,
and hepatitis C were associated with higher fracture rates.
Other bone turnover markers, other endocrinopathies,
transfusion and chelation histories, and childhood activity
were not signiﬁcantly associated with fracture rate. In a
multiple regression model selected by stepwise regression,
increased fracture rates were independently associated with
lower spine BMD Z-score, greater relative weight, and his-
tory of hepatitis C (Table 4).
Bone and joint pain
Thirty-four percent of participants reported having bone
or joint pain during the 30 days before enrollment (Fig. 5).
Six percent required prescription pain medications and an
additional 12.2% used over-the-counter analgesics (Table
2). Age, sex, and thalassemia syndrome were all indepen-
dent predictors of the presence and severity of bone and
joint pain (Table 4). The odds of more severe pain in-
creased 47% for each 5-yr age increment. Forty percent of
females but only 28% of males complained of recent pain.
Bone pain was reported more frequently among b TM par-
ticipants (40%) compared with b TI and E-b participants
(16% and 19%, respectively) (Fig. 5). Reported bone and
joint pain was not associated with bone mass or fractures.
Age at starting transfusion or chelation, units of blood
transfused, and ferritin and transferrin receptor concentra-
tions did not correlate with the presence or severity of bone
pain, indicating that iron overload and transfusion-related
parameters did not explain the higher frequency of bone
pain among TM participants. Participants with GH deﬁ-
ciency reported more severe bone pain (OR, 2.33; 95% CI,
1.11–4.76; p = 0.022), as did those with histories of medi-
cated heart disease, cirrhosis, or hepatitis C, but these were
not independent of age, sex, and thalassemia syndrome.
Hypogonadism, other endocrinopathies, serum vitamin D
concentrations, total calcium intake, and weight and height
measurements were not associated with bone pain. Partici-
pants who reported being more active at the time of the
study reported less pain, but this likely reﬂects the fact that
people in pain are usually less active, not the converse.
FIG. 2. Spine, femur, and total body BMD
Z-scores with a partial-linear spline (solid
line) and 95% CI (dashed lines). Individuals
>40 yr of age are omitted.
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550 VOGIATZI ET AL.Vertebral morphometry
Vertebral fractures: MXA was available in a total of 352
participants. Nine participants (2.6%) had evidence of ver-
tebral fractures by radiographic review, whereas only seven
participants (2.0%) reported a history of vertebral fracture
by interview. All vertebrae with radiographic evidence of
fracture had Genant compression deformity grades 2 or 3.
Eight of the nine participants with vertebral fractures were
b TM and one was b TI. The mean age was 48.6 ± 11.5 yr,
with the youngest being 37 yr of age. Vertebral fracture
prevalence increased with age (OR for 5-yr increase: 2.54;
95% CI, 1.74–4.29; p < 0.001). After controlling for age,
spine BMD Z-scores were negatively associated with frac-
tures (OR for 1-SD increase: 0.32; 95% CI, 0.12–0.71; p =
0.01). Neither sex, hypertransfusion regimen, years or age
at onset of DFO therapy, serum transferrin receptor or
ferritin concentration, endocrinopathies, or anthropometric
parameters correlated with fractures. Seven participants
with vertebral fractures were hypogonadal (78%), seven
reported back pain (78%), and all nine reported recent
bone and joint pain.
Vertebral growth disturbance: Thirty-one participants
(9.0%) had vertebral growth disturbances (VGDs) deﬁned
as a uniformly decreased height of several vertebrae. Preva-
lence of these abnormalities did not differ signiﬁcantly by
age, sex, or race. The mean age was 24.3 ± 4.3 yr (range,
18–34 yr). Twenty-nine (94%) of the participants with
VGD were b-TM. Among participants with b TM, initia-
tion of DFO therapy after age 6 yr (OR, 0.22; 95% CI,
0.10–0.45; p < 0.001), higher spine BMD Z-scores (OR for
1-SD increase, 0.57; 95% CI, 0.37–0.86; p = 0.009), and
increased urinary D-Pyr (OR for 2-fold increase, 0.15; 95%
CI, 0.05–0.40; p < 0.001) were all independently associated
with lower odds of VGD (Table 4). Whereas not an inde-
pendent predictor of VGD, hypogonadism was positively
associated (OR, 3.44; 95% CI, 1.50–8.39; p = 0.004) after
adjusting only for age. Presence of VGD was not speciﬁ-
cally correlated with either generalized bone pain, joint
pain, or back pain.
Eighteen (5.2%) participants evaluated for vertebral
morphometry had abnormalities that involved individual
vertebrae (e.g., presence of ring apophysis, platyspondyly,
Schmorl’s nodes; Table 2), 17 of whom were b TM. A total
of 45 participants (12.8%) had either VGD or isolated ver-
tebral abnormalities.
DISCUSSION
This study found a high prevalence of low BMD, frac-
tures, and bone pain in both b and a thalassemia syn-
dromes. It showed a strong association between bone mass
and fractures, and it identiﬁed factors that may contribute
to the pathogenesis of bone disease in thalassemia. Bone
disease would be expected to be less severe with mild or
moderate hemolysis, as is generally found in patients with b
TI, HbH disease, or HbH/CS. Indeed, bone mass was lower
among b TM and E-b and higher among b TI, HbH disease,
and HbH/CS. However, the effect of thalassemia syndrome
seemed to be caused by underlying differences in growth,
hypogonadism, and bone turnover, so that hypogonadal
and lighter patients with high bone turnover had a higher
likelihood of low BMD among all thalassemia syndromes.
Bone mass was reduced even in children—only 45% of 6-
to 10-yr-old participants had normal BMD. We found a
strong negative association between bone mass and age in
the 11- to 19-yr age group. Peak bone mass was suboptimal.
Short stature in some patients may have inﬂuenced these
results, which are based on areal BMD measurements.
However, the mean height Z-score was close to the popu-
lation mean, and correlations with volumetric BMD did not
suggest an important effect of bone size on our ﬁndings.
Lower weight and higher bone turnover were the only two
independent predictors of bone mass in patients <20 yr of
age, whereas hypogonadism, transfusion and chelation pa-
rameters, and family history of osteoporosis were not found
to play roles. These data indicate that adolescence is a criti-
cal period for the development of low bone mass in thalas-
semia and suggest that bone turnover plays a central role in
this process. Similar to other reports,
(23,24) we found in-
creased bone turnover in adults with thalassemia, regard-
less of hypogonadism, and our limited pediatric normative
data suggest that the same is true during adolescence. Al-
together, it is possible that the increased bone turnover
during this time does not allow for positive bone accrual
and attainment of optimal peak bone mass. Neither the
etiology of increased bone turnover in thalassemia nor a
possible disassociation between bone formation and resorp-
tion can be addressed in this study. One may hypothesize,
however, that the increased resorption in thalassemia re-
lates to a state of increased oxidative stress,
(25) which has
been shown to be present in these patients, and which can
also result in increased TNF production and bone loss.
(26,27)
FIG. 3. Prevalence of low (Z-score < 22
SD), reduced (22S D# Z-score < 21 SD),
and normal (Z-score $ 21 SD) spine and
femur Z-scores by thalassemia syndrome.
LOW BONE MASS AND FRACTURES IN THALASSEMIA 551Because current chelation and transfusion regimens have
remained largely unchanged in this cohort over the last 20
yr, it seems that current thalassemia therapies do not pre-
vent or retard the development of low bone mass.
Hypogonadism was a strong independent predictor of
low bone mass. Surprisingly, we did not ﬁnd higher BMD
among hypogonadal subjects who received gonadal steroid
replacement compared with those untreated. It is possible
that this is related to the cross-sectional design of the study,
the delayed or inadequate replacement with gonadal ste-
roids, or intermittent compliance with the prescribed treat-
ment. Gonadal steroid replacement schemes in females of
this study were frequently similar to the regimens used in
postmenopausal women, which may be inadequate for op-
timal bone accrual.
(28) Nonetheless, the potential beneﬁcial
effect of gonadal steroid replacement in thalassemia should
not be dismissed based on this study. An improvement of
BMD in thalassemia with gonadal steroid replacement has
been reported in some studies but not others.
(11,29–31) Thus,
this subject needs to be rigorously evaluated by longitudinal
randomized studies testing various types of gonadal re-
placement. Further longitudinal studies are also needed to
determine the optimal serum 25 vit D concentrations for
normal bone mass accrual and maintenance in thalasse-
mia,
(32,33) because we found high rates of vitamin D deﬁ-
ciency and insufﬁciency, as well as a negative and nonlinear
TABLE 3. RESULTS OF UNIVARIATE ANALYSES OF DXA BMD DATA*
Predictor Level/units
Spine Z-score Femur Z-score Whole body BMC (kg)
Regression coefﬁcient
(95% CI)
Regression coefﬁcient
(95% CI)
Regression coefﬁcient
(95% CI)
Demographics and anthropometrics
Age (5-yr increment) 06–20 yr 20.54 (20.68 to 20.41)
† 20.38 (20.52 to 20.25)
† 0.42 (0.38–0.47)
†
Sex Male vs. female 20.13 (20.35–0.09) 0.13 (20.09–0.35) 0.24 (0.17–0.31)
†
Race Asian vs. white 20.10 (20.34–0.13) 20.09 (20.33–0.14) 20.12 (20.19 to 20.05)
‡
Thalas clinical diagnosis BetaTI vs. b TM 0.22 (20.13–0.57) 0.48 (0.13–0.83)
x 0.14 (0.03–0.24)
x
Reported fractures 1–2 vs. zero 20.34 (20.61 to 20.07)
† 20.37 (20.63 to 20.10)
† 0.00 (20.08–0.09)
‡
Height Z-score SD 0.31 (0.22–0.40)
† 0.33 (0.24–0.42)
† 0.13 (0.11–0.16)
†
Weight Z-score SD 0.41 (0.33–0.49)
† 0.38 (0.30–0.47)
† 0.15 (0.12–0.17)
†
BMI Z-score SD 0.35 (0.26–0.45)
† 0.30 (0.20–0.40)
† 0.11 (0.08–0.14)
†
Bone turnover and endocrine markers
N-telopeptide, urinary log10(nM BCE/mM Creat) 20.76 (21.06 to 20.45)
† 20.61 (20.92 to 20.30)
† 20.19 (20.28 to 20.09)
†
Deoxypyridinium,
urinary
log10(nM/mM Creat) 21.36 (21.93 to 20.79)
† 21.20 (21.77 to 20.62)
† 20.36 (20.53 to 20.18)
†
Bone-speciﬁc alkaline
phosphatase
log10(U/liter) 21.34 (21.85 to 20.82)
† 21.32 (21.84 to 20.81)
† 20.40 (20.56 to 20.24)
†
IGF-1 log10(ng/ml) 0.62 (0.12–1.11)
x 0.65 (0.15–1.15)
x 0.36 (0.21–0.50)
†
IGFBP-3 mg/ml 0.15 (0.04–0.25)
‡ 0.12 (0.02–0.23)
x 0.05 (0.02–0.09)
‡
LH log10(U/liter) 0.29 (0.11–0.47)
‡ 0.40 (0.22–0.58)
† 0.14 (0.09–0.20)
†
FSH log10(U/liter) 0.39 (0.19–0.58)
† 0.52 (0.33–0.71)
† 0.18 (0.12–0.24)
†
Testosterone (males only) log10(ng/dL) 0.72 (0.48–0.97)
† 0.71 (0.48–0.94)
† 0.25 (0.17–0.33)
†
Chelation and transfusions
Transferrin receptor log10(mg/ml) 20.15 (20.52–0.22) 0.54 (0.17–0.91)
‡ 0.08 (20.03–0.19)
Ferritin log10(ng/ml) 20.20 (20.40–0.00) 20.16 (20.36–0.04) 20.07 (20.13 to 20.01)
x
Age started DFO therapy 6 ± vs. <6 yr 0.18 (20.21–0.57) 0.39 (0.03–0.74)
x 0.12 (0.01–0.23)
x
Thalassemia complications nutrition and physical activity
Hypogonadism Hypogonadal vs.normal 20.41 (20.90–0.09)
† 20.43 (20.91–0.04)
† 20.08 (20.23–0.07)
†
GH deﬁciency Yes vs/ no 20.71 (21.09 to 20.33)
† 20.80 (21.18 to 20.42)
† 20.26 (20.37 to 20.14)
†
Hypothyroidism Yes vs. no 0.04 (20.36–0.44) 20.51 (20.92 to 20.11)
x 20.09 (20.22–0.03)
Diabetes mellitus Yes vs. no 20.26 (20.65–0.13) 20.68 (21.07 to 20.29)
† 20.18 (20.30 to 20.06)
‡
Fasting blood glucose 100–125 vs. <100 mg/d 0.15 (20.19–0.50) 20.10 (20.44–0.25)
‡ 20.05 (20.15–0.06)
‡
25(OH) vitamin D Insufﬁcient vs. normal 0.15 (20.13–0.44)
† 0.28 (20.01–0.57)
‡ 0.11 (0.02–0.20)
†
Medicated heart disease Yes vs. no 20.60 (21.09 to 20.12)
x 20.68 (21.17 to 20.19)
‡ 20.06 (20.21–0.09)
Calcium intake log10(mg/d) 20.38 (20.77–0.00) 20.56 (20.95 to 20.17)
‡ 20.08 (20.21–0.04)
Childhood activity At least lightly active
versus very lightly
active
0.69 (0.02–1.35)
x 0.63 (20.05–1.31) 0.25 (0.03–0.46)
x
Only statistically signiﬁcant associations are presented. Additional nonsigniﬁcant tested associations included: age (5-yr increment 20–75 yr), race (others
vs. whites), additional clinical thalassemia diagnosis (i.e., E-b vs. b TM, HbH vs. b TM, HbH/CS vs. b TM), family history of osteoporosis or fractures,
b globin genotype for b TM patients, transfusion rate (ml/kg/mo), age started transfusions, years, and prescribed dose of DFO.
*Models for spine and femur BMD Z-scores included adjustments for age using a partial-linear spline. Models for whole body BMC included
adjustments for age (by partial-linear spline), sex, and race.
Signiﬁcance of categorical predictors indicates statistically signiﬁcant differences among levels and is indicated on the ﬁrst tabulated comparison. The
level of signiﬁcance is designated as follows:
†p < 0.001;
‡p < 0.01;
xp < 0.05.
BMI, body mass index; DFO, deferoxamine.
552 VOGIATZI ET AL.relationship between spine BMD and 25 vit D concentrations.
These ﬁndings may have signiﬁcant clinical implications be-
cause both screening and therapy of vitamin D deﬁciency
are easy, affordable, and beneﬁcial. Information about ﬂuc-
tuations in 25 vit D concentrations over the course of years
and their effect on the bone is not available in this study.
TABLE 4. RESULTS OF MULTIVARIATE ANALYSES OF SPINE BMD Z-SCORES,F EMUR BMD Z-SCORES,W HOLE BODY BMC,
FRACTURE RATE,P AIN SEVERITY, AND VERTEBRAL GROWTH DISTURBANCE
Predictor Comparison Parameter estimate* 95% CI p
Spine BMD Z-score
Age <0.0001
6–20 yr 1-yr increment 20.120 (20.156, 20.084)
20–75 yr 1-yr increment 20.008 (20.021, 0.005)
Weight Z 1-SD increment 0.394 (0.315, 0.472) <0.0001
Hypogonadism <0.0001
Delayed puberty vs. normal 20.210 (20.648, 0.229)
Hypogonadal vs. normal 20.601 (20.839, 20.363)
Deoxypyridinium, Ux 10-fold increase 21.090 (21.583, 20.597) <0.0001
25(OH) vitamin D 10-fold increase 0.571 (0.112, 1.030) 0.0150
Femur BMD Z-scores
Age <0.0001
6–20 yr 1-yr increment 20.103 (20.138, 20.068)
20–75 yr 1-yr increment 20.012 (20.026, 0.002)
Weight Z 1-SD increment 0.352 (0.274, 0.430) <0.0001
Hypogonadism 0.0003
Delayed puberty vs. normal 20.332 (20.766, 0.101)
Hypogonadal vs. normal 20.563 (20.836, 20.291)
Deoxypyridinium, Ux 10-fold increase 21.206 (21.687, 20.726) <0.0001
FSH 10-fold increase 0.238 (0.038, 0.438) 0.0197
Fasting BG 10-mg/dl increase 20.330 (20.560, 20.100) 0.0051
F.H. of osteoporosis Yes vs. no 20.298 (20.530, 20.065) 0.0123
Whole body BMC (kg)
Age <0.0001
6–20 yr 1-yr increment 0.085 (0.076, 0.094)
20–75 yr 1-yr increment 20.010 (20.013, 20.006)
Sex Male vs. female 20.284 (20.339, 20.229) <0.0001
Race 0.0031
Asian vs. white 20.097 (20.156, 20.038)
Other race vs. white 0.004 (20.109, 0.117)
Weight Z 1-SD increment 0.133 (0.111, 0.155) <0.0001
Hypogonadism <0.0001
Delayed puberty vs. normal 0.033 (20.083, 0.149)
Hypogonadal vs. normal 20.157 (20.230, 20.084)
BSALP 10-fold increase 20.208 (20.334, 20.082) 0.0013
FSH 10-fold increase 0.110 (0.057, 0.163) <0.0001
Serum creatinine 1-mg/dl increase 0.217 (0.085, 0.349) 0.0014
Fracture incidence rate
Spine BMD Z 1-SD increment 0.66 (0.559, 0.780) <0.0001
Weight Z 1-SD increment 1.31 (1.106, 1.551) 0.0017
Hepatitis C Yes vs. no 1.582 (1.091, 2.293) 0.0156
Pain severity
Age 5-yr increment 1.468 (1.313, 1.655) <0.0001
Sex Male vs. female 0.513 (0.312, 0.834) 0.0077
Thalassemia diagnosis 0.0006
b TI vs. b TM 0.47 (0.187, 1.069)
E-b vs. b TM 1.643 (0.735, 3.603)
HbH or HbH/CS vs. b TM 0.17 (0.060, 0.422)
Vertebral growth disturbance (among b TM only)
Spine BMD Z 1-SD increment 0.571 (0.367, 0.857) 0.0091
Deoxypyridinium, Ux 2-fold increase 0.146 (0.047, 0.401) 0.0004
Age started DFO After age 6 vs. before age 6 0.224 (0.096, 0.450) 0.0001
*Parameters for spine BMD Z-scores, femur BMD Z-scores, and whole body BMC are regression coefﬁcients from general linear models. Parameters
for fracture incidence rate are mean ratios from a proportional means model. Parameters for pain severity and vertebral growth disturbance are ORs from
ordinal and binary logistic regression models, respectively.
AP, anterior-posterior; Ux, urinary; F.H., family history; BG, blood glucose; BSALP, bone-speciﬁc alkaline phosphatase; DFO, deferoxamine.
LOW BONE MASS AND FRACTURES IN THALASSEMIA 553Overall, the cross-sectional design of this study constitutes
a limiting factor in our ability to infer the etiology of bone
disease in thalassemia. This limitation, as well as sample
size considerations, may also explain the lack of association
between bisphosphonate treatment and bone mass. In ad-
dition, because there was no control group, our data were
compared with standard databases, and the results should
be interpreted with this in mind.
Years on regular transfusions, DFO treatment, and trans-
fusion rates were used to assess the long-term effects of
thalassemia management and iron overload on the bone.
No association was found. Current degree of iron overload
(assessed by serum ferritin concentration) was also not as-
sociated with bone disease. It is possible that the role of iron
in the pathogenesis of the disease was missed because we
lacked a deﬁnitive marker of iron overload. Ferritin is a
poor marker in heavily overloaded individuals. Other mea-
sures of iron excess, for example, liver biopsy, superconduc-
tive quantum interference device (SQUID), or MRI, were
not performed in this study. Finally, ineffective erythropoi-
esis (assessed by serum transferrin receptor concentrations)
was not associated with bone mass, with the exception of an
association with femur BMD in univariate analysis of unclear
biological signiﬁcance.
The fracture prevalence based on both patient history
and medical record review was 36%. This is substantially
lower than the rates of 50% reported in 1960s and 1970s.
(34)
Our present results differ from a recent TCRN report that
observed an overall fracture prevalence of 12%.
(35) The
latter report
(35) most likely underestimated the fracture
prevalence because of its reliance on chart review of a
TCRN established database that was generic in nature and
not comprehensive for prior bone problems. In this study,
E-b and a thalassemias were found to have lower rates of
fractures compared with b TM. However, as in the case of
our BMD results, neither thalassemia syndrome nor chela-
tion and transfusion parameters were signiﬁcant indepen-
dent predictors of fracture rates in multivariate analysis.
Instead, a strong association between BMD and fracture
rate was observed. We also found that, in these patients, as
FIG. 4. Bone turnover markers vs. age
stratiﬁed by sex and hypogonadal status (hy-
pogonadal, +; not hypogonadal, s) with age-
dependent upper and lower limits of normal
(dashed lines). One individual age 75 yr is
omitted.
554 VOGIATZI ET AL.in osteoporotic patients, the cumulative risk for fractures
increased with age in an almost linear fashion. A bimodal
fracture distribution with one peak related to sports activi-
ties among adolescent males and a second rise related to
osteoporosis among postmenopausal females has been de-
scribed in the general population.
(36–38) Such a bimodal
fracture risk was not observed among our patients. Similar
to the previous retrospective TCRN study,
(35) children and
adolescents did not seem to be at increased risk for frac-
tures. This ﬁnding may be related to the cross-sectional
design of our study or to the decreased level of physical
activity in this patient population.
Whereas long bone metaphyseal irregularities and abnor-
mal vertebral bodies resembling bone dysplasias have been
described in b TM and attributed to DFO toxicity,
(39) the
presence and etiology of these abnormalities given today’s
standard of care are largely unknown. This is the ﬁrst study
in thalassemia to use vertebral morphometry to evaluate a
large number of patients for such abnormalities. Indeed, a
large number of deformities were found, mostly VGDs
characterized by decreased height of multiple vertebrae.
VGD occurred exclusively in regularly transfused and che-
lated patients with b TM and E-b, were associated with
early use of DFO (before age 6), and occurred regardless of
age, with the youngest affected patient being 18 yr old. A
rather small number of vertebral fractures were docu-
mented, found primarily in patients with b TM. Vertebral
fractures increased with age and were related to low bone
mass and hypogonadism. These data suggest different eti-
ologies between vertebral fractures and deformities, and in
particular, the role of early treatment with DFO in the
development of vertebral deformities in thalassemia.
Despite its high prevalence, the etiology of bone pain in
our patients remains obscure. There was no correlation
with history of fractures or vertebral deformities, except in
those with documented vertebral fractures by morphom-
etry, who almost always reported bone pain. Bone pain
increased with age and was more frequent among females,
despite fractures rates similar to those of males. Patients
with b TM also reported bone pain more frequently than
those with other thalassemia syndromes, although we were
unable to establish any transfusion or chelation related pa-
rameter as a possible contributor to pain. Neither endocri-
nopathy, other thalassemia complications, nor vitamin D
deﬁciency were independent predictors of bone pain. Why
females with b TM are more prone to bone pain remains
uncertain.
In summary, in this large cohort of patients across all
thalassemia syndromes, we observed a high prevalence of
fractures and a strong association between bone mass and
fractures. Therefore, strategies to improve BMD are very
important in thalassemia management. We showed that
bone disease in thalassemia is an adolescent problem with
adult manifestations. Current transfusion and chelation
practices seem insufﬁcient to prevent the development of
low bone mass. Our data highlight the need for randomized
trials to determine the appropriate form of gonadal steroid
replacement and vitamin D supplementation as well as ad-
ditional strategies to optimize bone accrual in this disease.
Further longitudinal studies are needed to address changes
of bone mass during puberty. Finally, changes in bone turn-
over seem to be involved in the development of bone dis-
ease, although the factors that lead to increased bone re-
sorption in thalassemia remain unclear and warrant further
study.
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This is Publication 6 of the Thalassemia Clinical Research Net-
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Investigator, Janet L Kwiatkowski, MD, Co-Principal Investigator,
556 VOGIATZI ET AL.Catherine S Manno, MD, Coinvestigator, Marie Martin, RN, Nurse
Coordinator, DebraHillman, RegulatoryAffairsCoordinator, Gail
M Jackson, CDT, Nutrition Assessment Program Coordinator,
Maria J Henwood-Storto, DO, Endocrinologist; Shannon H
Fourtner, MD, Endocrinologist; Childrens Hospital & Research
CenterOakland:ElliottVichinsky,MD,PrincipalInvestigator,Dru
Foote, NP, Study Coordinator, Eun-Ha Pang, Study Coordinator,
Zahra Pakbaz, MD, CCD, Certiﬁed Clinical Densitometrist,
Selma Holden, Study Coordinator; Toronto General Hospital:
Nancy Olivieri, MD, Principal Investigator; U.T. Southwestern
Medical Center: Charles T Quinn, MD, Assistant Professor of
Pediatrics, Elizabeth Shull, BSN, RN, Clinical Research Associ-
ate; Weill Medical College of Cornell University: Patricia J Giardina,
MD, Principal Investigator, Robert W Grady, PhD, Co-Investigator,
Jeffrey E Mait and Dorothy Kleinert, NP, MPH, MA, Study Coor-
dinators, Irina Chaikhoutdinov and Gladys Cintron, Data Coordi-
nators, Sylvia Hom, DXA Technician, Hospital for Special Surgery;
National Heart, Lung, and Blood Institute: Charles Peterson, MD,
Project Ofﬁcer; Data Coordinating Center, New England Research
Institutes: Sonja McKinlay, PhD, Principal Investigator, Felicia
Trachtenberg, PhD, Statistician, Haddy Jallow, MS, MPH, Project
Coordinator.
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